Mansfield Bio-Incubator的封面图片
Mansfield Bio-Incubator

Mansfield Bio-Incubator

生物技术研究

Mansfield,MASSACHUSETTS 1,144 位关注者

A Collaborative Environment To Help Ensure Your Success

关于我们

As a non-profit, our mission is to assist early-stage start-ups and entrepreneurs in the generation of innovative research and education in the fields of biotechnology, medical therapeutics, life sciences and beyond. To accomplish this we: 1) provide our residents with fully equipped and staffed lab and office space built using modern design principles 2) assist with applications for government and private funding for research, development and generation of a viable business plan 3) provide a range of professional business services from IT, to legal to accounting 4) offer educational opportunities via our mentorship program, memberships to key trade organizations, seminars, access to courses and networking events 5) access to our Advisory Board with expertise ranging from science, to business and entrepreneurship 6) create a collaborative environment that stimulates creative interactions amongst industry, investors, government and academia 7) maintain collaboration with premier research and academic institutions. The facility is conveniently located close to the cross-section of Routes I-95 and I-495, walking distance from the Commuter Rail, and short driving distance from the hubs of Providence and Boston/Cambridge.

网站
https://www.bioinc.org/
所属行业
生物技术研究
规模
2-10 人
总部
Mansfield,MASSACHUSETTS
类型
非营利机构
创立
2017
领域
Life Sciences、Laboratory、Incubator、Start-ups、Biotechnology、Medical Devices、Diagnostics、Therapeutics、Cannabinoids、Health和Life Science Instrumentation

地点

  • 主要

    241 Francis Avenue

    US,MASSACHUSETTS,Mansfield,02048

    获取路线

Mansfield Bio-Incubator员工

动态

  • 查看Mansfield Bio-Incubator的组织主页

    1,144 位关注者

    What a great achievement for Yuji Otsuki FerroptoCure Inc., our member company!

    查看FerroptoCure Inc.的组织主页

    206 位关注者

    We at FerroptoCure Inc. are very pleased to announce that our CEO, Yuji Otsuki, has been awarded the Mitsubishi Estate Award (三菱地所賞) at the UPDATE EARTH event held on March 15th, 2025. We are honored to receive such recognition in our efforts to bring a new era of ferroptosis-based cancer therapeutics to patients worldwide. Please see the press release and a full list of Awardees below at: https://lnkd.in/eSrh-Qzh #FerroptoCure #Innovation #Biotech

    • 该图片无替代文字
  • 查看Mansfield Bio-Incubator的组织主页

    1,144 位关注者

    For #biotech #startups out there: now that your think that you secured the covered #seriesa, hold off the celebration and look at the #termsheet carefully to check for the catches lurking beneath the surface to avoid signing the #deal that could hurt you long-term. A very sage advice.

    查看Charlotte Ketelaar的档案

    Founder @Capwave AI | Fundraising co-pilot | VC matches | $400M+ raised | Angel Investor | ex-Investment Banker

    The first time I looked at a VC term sheet, I made the classic founder move: Scanned for valuation. Mentally celebrated. Big mistake. Because the stuff that actually matters? It’s hidden in the fine print. Here are 3 terms that quietly screw over founders: 1) Liquidation Preference – If it’s 2x participating, investors get paid twice before you see a dime. That “big exit”? Might feel more like a rounding error. 2) Board Control – You built the company, but if the board’s stacked with VCs… they can fire you. Even if you’re hitting your numbers. 3) Option Pool Shuffle – If VCs ask to increase the option pool before they invest, guess who gets diluted? You. Always ask: pre- or post-money? Too many founders learn this stuff the hard way. You don’t raise your Series A to get blindsided. >> Read the term sheet. >> Understand the incentives. >> Protect your equity. What’s the sneakiest term you’ve seen on a VC term sheet? Did you negotiate your first deal solo or bring in a lawyer? What’s one thing you wish you knew before signing? Teaser: we are working on an agent that will make sure that you don't sign your company away: upload and we will flag what you need to know. #startups #founders #venturecapital #fundraising

    • 该图片无替代文字
  • The Massachusetts Life Sciences Center’s Massachusetts Next Generation (#MassNextGen) Initiative supports a broad network of underrepresented entrepreneurs through #funding, coaching, and network building. This initiative will be accepting applications from March 17 to June 13, 2025.?Learn more. https://lnkd.in/eRrzK8X We are proud partner with the MLSC and host an in-person info session for the Massachusetts Next Generation (MassNextGen) Initiative on April 2nd at 11 a.m at Mansfield Bio-Incubator. Please register to attend here. https://lnkd.in/eTaExsfR

  • Exciting News from Mansfield Bio-Incubator! We are thrilled to announce that Wuhan Servicebio Technology Co., Ltd. has joined our community as our newest member! Servicebio is a leading manufacturer specializing in lab equipment, reagents, and consumables for the life sciences industry. With a strong workforce of over 3,000 employees, its headquarters in Hubei, China, and a warehouse in New Jersey, this move to establish a presence in one of the world’s largest life science hubs marks a strategic milestone in the company's growth trajectory. Here’s what some key leaders had to say about this exciting development: Teena Che Sales Director of Servicebio, commented on the significance of this new chapter: “We are excited to become part of the Mansfield Bio-Incubator community. This marks a pivotal moment in Servicebio's global expansion strategy, allowing us to better serve the growing demands of the life sciences industry in the United States. Our presence in Massachusetts will strengthen our ability to deliver high-quality lab equipment, reagents, and consumables to researchers and institutions in one of the world's largest biotech hubs. We are looking forward to building strong partnerships and contributing to the continued innovation in life science research.” Alexander Margulis, Ph.D., Chief Operating Officer of Mansfield Bio-Incubator, also shared his perspective: “I was impressed with Servicebio’s portfolio as the company’s products are high-quality and cover the needs of the researchers extremely well. Mansfield Bio-Incubator is happy to help promote Servicebio?in this top-ranked, highly competitive market.” Stay tuned for more updates as Servicebio embarks on this new and exciting journey! #Servicebio #LifeSciences #Expansion #Innovation #GlobalGrowth #Welcome #Massachusetts #Labspace #startups #biotech

    • 该图片无替代文字
    • 该图片无替代文字
  • We are thrilled to support #Massnextgen and wish the cohort #success #lifesciences #biotech #massachusetts. Thank you Massachusetts Life Sciences Center for this initiative.

    查看Massachusetts Life Sciences Center的组织主页

    11,679 位关注者

    "Together, we are helping create a community where entrepreneurs of every background can feel welcomed, valued, and empowered to succeed.” This week we announced the 7th cohort of awardees of the Massachusetts Next Generation (MassNextGen) Initiative, a public-private partnership to support underrepresented entrepreneurs in the Massachusetts life sciences sector. Four companies will receive awards of $60,000 per company, including additional funds and in-kind services from MassNextGen sponsors. Congratulations DoriNano, Gelectric Medical, General Prognostics (GPx), and Barlume Cosmetics. Thank you to Johnson & Johnson Innovation for hosting our celebration event. We are grateful for?Anchor Platinum Sponsor, Takeda, as well as all of our MassNextGen sponsors: Massachusetts Biomedical Initiatives (MBI), ABI-LAB, Berkshire Innovation Center, Cambridge Scientific Labs, Hatch.Bio Labs, InnoVenture Labs , UMassM2D2, Mansfield Bio-Incubator, Portal Innovations, LLC, and the Venture Development Center at UMass Boston. Read more: https://lnkd.in/e-Cp55zk

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
      +1
  • Great to see the private sector stepping up to offset the loss of #SBIR #NIH #funding

    查看Chris Gibson的档案

    Co-Founder/CEO & Director of Recursion: a biotech scaling more like a tech company - Nasdaq:RXRX | Boards: Cellino, BioHive, Salt Lake Tribune | Angel/friend of deeptech founders and dreamers

    Today, we are announcing a new pre-seed venture fund – Altitude Lab Fund – to support early-stage biotech startups facing the loss of SBIR grants due to recent federal funding policy shifts which have left many biotech founders in limbo. I wrote about why these funds are so critical – and why this moment represents a call to action in the industry –? in an op-ed for STAT. Namely, NIH and SBIR funding led to the formation of leading biotechs and breakthroughs – from monoclonal antibody therapies, to the COVID-19 vaccine, to advances in CRISPR technology, AIDS treatments, and the HPV vaccine. Recursion benefited from these funds, too – both to support the early research that led to our founding – and, after it was founded, receiving $3.5 million in NIH Small Business Innovative Research (SBIR) grants, which helped us get off the ground. We’ve since raised more than 400 times our SBIR funding in private investment to advance our platform and improve the way drugs are discovered. Today, we are a $4 billion publicly-traded company with 8 therapeutics in clinical trials, more than 10 in advanced discovery, and R&D partnerships with leading pharmas. And we believe that there are many other worthwhile biotech companies that need that same support to lead to the next great American medical breakthrough – and that we as an industry need to step up. The Altitude Lab Fund – anchored by myself and biotech entrepreneur David Bearss Ph.D. – will provide:? ●? ? $100,000–$250,000 in pre-seed investment capital ●? ? ? 12 months of lab and office space ●? ? ? Admission to the competitive accelerator program run by our incubator, Altitude Lab in Salt Lake City, which includes exclusive mentorship and access to top tier national funds. Learn more about the fund: https://lnkd.in/gtCXvUUz Read my op-ed: https://lnkd.in/gwKYsPch Read the story in TechCrunch: https://lnkd.in/gymzEZVu CEO of a company caught in the SBIR-funding turmoil with a great impact score and interested in the Altitude Lab Fund? https://lnkd.in/gKEvs8j5

    • 该图片无替代文字
  • Mansfield Bio-Incubator转发了

    查看Chris Gibson的档案

    Co-Founder/CEO & Director of Recursion: a biotech scaling more like a tech company - Nasdaq:RXRX | Boards: Cellino, BioHive, Salt Lake Tribune | Angel/friend of deeptech founders and dreamers

    Today, we are announcing a new pre-seed venture fund – Altitude Lab Fund – to support early-stage biotech startups facing the loss of SBIR grants due to recent federal funding policy shifts which have left many biotech founders in limbo. I wrote about why these funds are so critical – and why this moment represents a call to action in the industry –? in an op-ed for STAT. Namely, NIH and SBIR funding led to the formation of leading biotechs and breakthroughs – from monoclonal antibody therapies, to the COVID-19 vaccine, to advances in CRISPR technology, AIDS treatments, and the HPV vaccine. Recursion benefited from these funds, too – both to support the early research that led to our founding – and, after it was founded, receiving $3.5 million in NIH Small Business Innovative Research (SBIR) grants, which helped us get off the ground. We’ve since raised more than 400 times our SBIR funding in private investment to advance our platform and improve the way drugs are discovered. Today, we are a $4 billion publicly-traded company with 8 therapeutics in clinical trials, more than 10 in advanced discovery, and R&D partnerships with leading pharmas. And we believe that there are many other worthwhile biotech companies that need that same support to lead to the next great American medical breakthrough – and that we as an industry need to step up. The Altitude Lab Fund – anchored by myself and biotech entrepreneur David Bearss Ph.D. – will provide:? ●? ? $100,000–$250,000 in pre-seed investment capital ●? ? ? 12 months of lab and office space ●? ? ? Admission to the competitive accelerator program run by our incubator, Altitude Lab in Salt Lake City, which includes exclusive mentorship and access to top tier national funds. Learn more about the fund: https://lnkd.in/gtCXvUUz Read my op-ed: https://lnkd.in/gwKYsPch Read the story in TechCrunch: https://lnkd.in/gymzEZVu CEO of a company caught in the SBIR-funding turmoil with a great impact score and interested in the Altitude Lab Fund? https://lnkd.in/gKEvs8j5

    • 该图片无替代文字
  • 查看Mansfield Bio-Incubator的组织主页

    1,144 位关注者

    We are proud to partner with?MassMEDIC ?on their Medtech Impact Symposium & Gala on March 6 in Boston, MA! A limited number of tickets still remain for the Symposium! Register now to participate in an uncommonly candid day-long discussion of how the industry is changing and how we position ourselves to succeed.?https://lnkd.in/e997JQ8Z?? ? ?Pro tip: use our partner code PARTNER100 to save $100 on regular priced Symposium tickets!???? ? With three General Sessions featuring leaders from?Insulet Corporation,?Pristine Surgical,?ZOLL Medical Corporation,?Mass General Brigham,?Battelle,?Medtronic,?Johnson & Johnson MedTech,?Adagio Medical Inc.,?Hologic, Inc.,?Cambridge Consultants, and more, you’ll hear from leading experts about today’s evolving ecosystem and how we prepare for 2030.? ? Diving into three concurrent track sessions, you’ll get to choose from conversations in cardiac, musculoskeletal health and diabetes. Sessions include: product trends and clinical successes driving medtech forward; forward thinking sessions that contemplate our shifting landscape; an inside look into policy “what ifs”, and an exclusive fireside chat with Michael Minogue, former CEO of?Abiomed, as we dig into lessons learned from a journey in medtech, led by?The Mullings Group.? ? Don’t miss out! Registration closes on Feb. 28. We’ll see you there!? ? #medtechimpact #symposium #gala #patientimpact #medtech #heartofhealthtech

    • 该图片无替代文字

相似主页

查看职位

融资